Evidence map›Paper›PMID 34206355›Full record

ReviewJournal of cardiovascular development and disease2021

Direct Reprogramming of Cardiac Fibroblasts to Repair the Injured Heart.

Emma Adams, Rachel McCloy, Ashley Jordan, Kaitlin Falconer, Iain M Dykes

Open access · goldAbstract readReview
In one paragraph

Review in Journal of cardiovascular development and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration.International journal of molecular sciences · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Emma AdamsPharmacy and Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK.
Rachel McCloyPharmacy and Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK.
Ashley JordanPharmacy and Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK.
Kaitlin FalconerPharmacy and Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK.
Iain M DykesPharmacy and Biomolecular Science, Liverpool John Moores University, Liverpool L3 3AF, UK.ORCID 0000-0002-1030-3721
Liverpool John Moores University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary heart disease is a leading cause of mortality and morbidity. Those that survive acute myocardial infarction are at significant risk of subsequent heart failure due to fibrotic remodelling of the infarcted myocardium. By applying knowledge from the study of embryonic cardiovascular development, modern medicine offers hope for treatment of this condition through regeneration of the myocardium by direct reprogramming of fibrotic scar tissue. Here, we will review mechanisms of cell fate specification leading to the generation of cardiovascular cell types in the embryo and use this as a framework in which to understand direct reprogramming. Driving expression of a network of transcription factors, micro RNA or small molecule epigenetic modifiers can reverse epigenetic silencing, reverting differentiated cells to a state of induced pluripotency. The pluripotent state can be bypassed by direct reprogramming in which one differentiated cell type can be transdifferentiated into another. Transdifferentiating cardiac fibroblasts to cardiomyocytes requires a network of transcription factors similar to that observed in embryonic multipotent cardiac progenitors. There is some flexibility in the composition of this network. These studies raise the possibility that the failing heart could one day be regenerated by directly reprogramming cardiac fibroblasts within post-infarct scar tissue.

Indexed as

heart failureinduced pluripotent stem cellmyocardial infarctionregenerative medicinereprogrammingstem cell

Identifiers

PMID34206355
PMCPMC8306371
OpenAlexW3175476599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.